Search
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Boehringer partners with NCD Alliance
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
World water day 2019
Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards